Ipamorelin 10mg

Ipamorelin (10mg) — Research Compound

Ipamorelin is a selective ghrelin receptor agonist and growth hormone secretagogue. Unlike earlier compounds in its class, Ipamorelin is studied for its high degree of selectivity, triggering growth hormone release without significantly affecting prolactin, cortisol, or ACTH levels. Researchers investigate Ipamorelin for its ability to mimic the pulsatile release of endogenous growth hormone and its subsequent impact on cellular repair, bone density, and lipid metabolism.

Findings from early-stage clinical trials have reported:

• Potent and pulsatile increases in plasma growth hormone levels observed following administration
  
• Improvements in gastric motility and the rate of gastric emptying reported in experimental models
  
• Enhanced bone mineral density and increased bone formation markers noted in-vivo
  
• Reductions in body fat percentage alongside the preservation of lean muscle mass reported in research studies
  

Researchers utilise Ipamorelin to study the regulation of the somatotropic axis and the physiological benefits of targeted growth hormone secretion. Its selective nature makes it an ideal tool for investigating long-term metabolic enhancements without the side effects associated with broader secretagogues. This makes it a primary focus for research into age-related growth hormone deficiency and recovery optimization.

Available Formats:
This compound is available as a vial of lyophilised powder, or can be ordered in a disposable pen, a reusable pen, or a cartridge for an existing reusable pen system.

Used solely for in vitro experiments and cannot be:

• Used in clinical trials involving humans
• Administered to humans as part of an experiment or investigation
• Supplied to another party for human investigational use